Advertisement
| epclusa duration of therapy: Liver Pathophysiology Pablo Muriel, 2017-03-02 Liver Pathophysiology: Therapies and Antioxidants is a complete volume on morphology, physiology, biochemistry, molecular biology and treatment of liver diseases. It uses an integral approach towards the role of free radicals in the pathogenesis of hepatic injury, and how their deleterious effects may be abrogated by the use of antioxidants. Written by the most prominent authors in the field, this book will be of use to basic and clinical scientists and clinicians working in the biological sciences, especially those dedicated to the study and treatment of liver pathologies. - Presents the most recent advances in hepatology, with a special focus on the role of oxidative stress in liver injury. - Provides in vivo and in vitro models to study human liver pathology. - Explains the beneficial effects of antioxidants on liver diseases. - Contains the most recent and modern treatments of hepatic pathologies, including, but not limited to, stem cells repopulation, gene therapy and liver transplantation. |
| epclusa duration of therapy: Chronic Hepatitis C Virus Mitchell L. Shiffman, 2011-11-17 Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV. |
| epclusa duration of therapy: Guidelines on Hepatitis B and C Testing World Health Organization, 2017 Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations. |
| epclusa duration of therapy: FDA's Drug Review Process and the Package Label Tom Brody, 2017-12-01 FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. - Reveals strategies for winning FDA approval and for drafting the package label - Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases - This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug |
| epclusa duration of therapy: Frequently Prescribed Medications Michael Mancano, Jason Gallagher, 2010-11-12 Health Sciences & Professions |
| epclusa duration of therapy: HIV Psychiatry James A. Bourgeois, Mary Ann Adler Cohen, Getrude Makurumidze, 2021-11-18 This book is a practical guide in understanding how to prevent HIV transmission, to recognize risk behaviors, and to add something else to their repertoires. It aims to empower clinicians and provide a sense of security and competence with the recognition and understanding of some of the psychiatric illnesses that complicate and perpetuate the HIV pandemic that continue to persist throughout every area of the world despite the magnitude of the progress that has transformed the illness from a rapidly fatal to chronic illness that is no longer life-limiting. Missing in most of the literature on HIV is the subtle, and sometimes not so subtle, contribution of psychiatric symptoms, psychiatric illness, and risk behaviors that drive the pandemic and serve as catalysts for new infections. This practical guide provides state-of-the-art understanding of not only prevention but also a way to recognize risk behaviors, psychiatric symptoms, and psychiatric illnesses that will demystify and decode the sometimes enigmatic and frustrating reasons for nonadherence with diagnostic procedures and life-saving treatments and care. All behaviors and pathology are covered as well as the resources and treatments available. The goal of this text is to refresh knowledge on the current state of psychiatric illness management among people living with HIV, to provide a concise volume on the psychiatric aspects of HIV prevention and treatment that substantially impact the overall care of the patient, and to help understand the psychiatric catalysts of the pandemic Written by experts in the field, HIV Psychiatry: A Practical Guide for Clinicians provides enduring guidance to medical and other professionals caring for complicated clinical patients as they face ongoing challenges in working with persons with HIV and AIDS. |
| epclusa duration of therapy: Memorizing Pharmacology: A Relaxed Approach Tony Guerra, 2015-12-31 As a working parent of 4-year-old triplet daughters, I understand time management presents one of the greatest barriers to my pharmacology students' success. Many students feel that cold sense of overwhelm and information overload. This easy-to-read guide organizes pharmacology into manageable, logical steps you can fit in short pockets of time. The proven system helps you memorize medications quickly and form immediate connections. With mnemonics from students and instructors, you'll see how both sides approach learning. After you've finished the 200 Top Drugs in this book, reading pharmacology exam questions will seem like reading plain English. You'll have a new understanding of pharmacology to do better in class, clinical and your board exam. You'll feel the confidence you'd hoped for as a future health professional. For patients and caregivers, this book provides a means to memorize medications to quickly and articulately communicate with your health providers. |
| epclusa duration of therapy: Hepatitis C: Care and Treatment Angelos Hatzakis, 2021-05-10 This volume provides the reader with a detailed overview of the current state-of-the art approach of Hepatitis C management. It reviews the course of action in handling of chronic Hepatitis C patients with various HCV genotypes and treats special cases such as acute hepatitis, transplant and renal patients as well as people who inject drugs. The two volume work on Hepatitis C introduces to the topic by reviewing virology, diagnosis, epidemiology, prevention, management and elimination of HCV. The book provides a valuable source at full length for researchers and clinicians working on Hepatitis C. |
| epclusa duration of therapy: Conn's Current Therapy 2024 - E-Book Rick D. Kellerman, David P. Rakel, Joel J. Heidelbaugh, 2023-11-29 **Selected for Doody's Core Titles® 2024 with Essential Purchase designation in Family Medicine**Trusted by clinicians for more than 75 years, Conn's Current Therapy presents today's evidence-based information along with the personal experience and discernment of expert physicians. The 2024 edition is a helpful resource for a wide range of healthcare providers, including primary care physicians, subspecialists, and allied health professionals, providing current treatment information in a concise yet in-depth format. Nearly 350 topics have been carefully reviewed and updated to bring you state-of-the-art content in even the most rapidly changing areas of medicine. - Offers personal approaches from recognized leaders in the field, covering common complaints, acute diseases, and chronic illnesses along with the most current evidence-based clinical management options. - Follows a consistent, easy-to-use format throughout, with diagnosis, therapy, drug protocols, and treatment pearls presented in quick-reference boxes and tables for point-of-care answers to common clinical questions. - Incorporates electronic links throughout the text that connect the reader to apps and clinical prediction tools that can easily be accessed in practice. - Features thoroughly reviewed and updated information from multiple expert authors and editors, who offer a fresh perspective and their unique personal experience and judgment. - Provides current drug information thoroughly reviewed by PharmDs. - Features nearly 300 images, including algorithms, anatomical illustrations, and photographs, that provide useful information for diagnosis. |
| epclusa duration of therapy: Conn's Current Therapy 2017 E-Book Edward T. Bope, Rick D. Kellerman, 2016-10-10 Covering more than 300 clinically relevant topics, Conn’s Current Therapy 2017 by Drs. Edward T. Bope and Rick D. Kellerman offers an in-depth, personal approach to treatment from international experts, ideally suited for today’s busy medical practitioners. Trustworthy and easy to use, this annually updated resource focuses solely on the most current treatment protocols for common complaints, acute diseases, and chronic illnesses you’re likely to see. New chapters and numerous new authors in this edition bring you fully up to date on the topics you need to know about for effective patient care. Reliable, in-depth, systems-based content suitable for all first-line-of-defense providers. Thorough PharmD review of recently approved and soon-to-be approved drugs. Easy access to the latest evidence-based treatment practices for the most effective results. More than 400 easy-to-understand tables make referencing complex data quick and easy. Nearly 300 images, including algorithms, anatomical illustrations, and photographs, provide useful information for diagnosis. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Easy access to the latest evidence-based treatment practices for the most effective results. Seven new chapters cover palliative care, pancreatic cancer, babesiosis, Zika virus, sexual dysfunction, bronchiolitis, and failure to thrive. New authors provide a fresh perspective and their personal approach to scores of conditions and topics, including arboviruses and other emerging viruses. |
| epclusa duration of therapy: Geriatric Gastroenterology C. S. Pitchumoni, T. Dharmarajan, 2012-07-26 As aging trends in the United States and Europe in particular are strongly suggestive of increasingly older society, it would be prudent for health care providers to better prepare for such changes. By including physiology, disease, nutrition, pharmacology, pathology, radiology and other relevant associated topics, Geriatric Gastroenterology fills the void in the literature for a volume devoted specifically to gastrointestinal illness in the elderly. This unique volume includes provision of training for current and future generations of physicians to deal with the health problems of older adults. It will also serve as a comprehensive guide to practicing physicians for ease of reference. Relevant to the geriatric age group, the volume covers epidemiology, physiology of aging, gastrointestinal physiology, pharmacology, radiology, pathology, motility disorders, luminal disorders, hepato-biliary disease, systemic manifestations, neoplastic disorders, gastrointestinal bleeding, cancer and medication related interactions and adverse events, all extremely common in older adults; these are often hard to evaluate and judge, especially considering the complex aging physiology. All have become important components of modern medicine. Special emphasis is be given to nutrition and related disorders. Capsule endoscopy and its utility in the geriatric population is also covered. Presented in simple, easy to read style, the volume includes numerous tables, figures and key points enabling ease of understanding. Chapters on imaging and pathology are profusely illustrated. All chapters are written by specialists and include up to date scientific information. Geriatric Gastroenterology is of great utility to residents in internal medicine, fellows in gastroenterology and geriatric medicine as well as gastroenterologists, geriatricians and practicing physicians including primary care physicians caring for older adults. |
| epclusa duration of therapy: The Liver Irwin M. Arias, Harvey J. Alter, James L. Boyer, David E. Cohen, David A. Shafritz, Snorri S. Thorgeirsson, Allan W. Wolkoff, 2020-03-09 Bridging the gap between basic scientific advances and the understanding of liver disease — the extensively revised new edition of the premier text in the field. The latest edition of The Liver: Biology and Pathobiology remains a definitive volume in the field of hepatology, relating advances in biomedical sciences and engineering to understanding of liver structure, function, and disease pathology and treatment. Contributions from leading researchers examine the cell biology of the liver, the pathobiology of liver disease, the liver’s growth, regeneration, metabolic functions, and more. Now in its sixth edition, this classic text has been exhaustively revised to reflect new discoveries in biology and their influence on diagnosing, managing, and preventing liver disease. Seventy new chapters — including substantial original sections on liver cancer and groundbreaking advances that will have significant impact on hepatology — provide comprehensive, fully up-to-date coverage of both the current state and future direction of hepatology. Topics include liver RNA structure and function, gene editing, single-cell and single-molecule genomic analyses, the molecular biology of hepatitis, drug interactions and engineered drug design, and liver disease mechanisms and therapies. Edited by globally-recognized experts in the field, this authoritative volume: Relates molecular physiology to understanding disease pathology and treatment Links the science and pathology of the liver to practical clinical applications Features 16 new “Horizons” chapters that explore new and emerging science and technology Includes plentiful full-color illustrations and figures The Liver: Biology and Pathobiology, Sixth Edition is an indispensable resource for practicing and trainee hepatologists, gastroenterologists, hepatobiliary and liver transplant surgeons, and researchers and scientists in areas including hepatology, cell and molecular biology, virology, and drug metabolism. |
| epclusa duration of therapy: Clinical Use of Anti-infective Agents Robert W. Finberg, Roy Guharoy, 2021-07-23 This second edition of Clinical Use of Anti-Infective Agents provides a comprehensive overview of current approaches to using drugs to treat infections, including historical perspectives, definitions, and discussion of pharmacokinetics and pharmacodynamics and their uses. It includes a detailed explanation of different classes of drugs, outlining their spectrum, pharmacokinetics, side effects, and dosing in clinical settings. This book has been designed as a reference tool for pharmacists, clinicians, nurse practitioners, and clinical microbiologists, as well as a teaching vehicle for students studying infection and patient treatment. Each section includes references allowing for in-depth study of specific agents, Q&As, and illustrative case studies accompanied by commentary on how to approach patients and organisms, optimal methods of making a diagnosis, and prescribing treatment. |
| epclusa duration of therapy: Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters Shuguang Ma, Swapan Chowdhury, 2020-07-10 Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters, Second Edition, is completely updated to provide an overview of the last decade's numerous advances in analytical technologies for detection and quantification of drugs, metabolites, and biomarkers. This new edition goes beyond LC-MS and features all-new chapters on how to evaluate drug absorption, distribution, metabolism, and excretion, potential for hepatic and renal toxicity, immunogenicity of biotherapeutics and translational tools for predicting human dosage, safety and efficacy of small molecules and biologics. This book will be an important handbook and desk reference for pharmacologists, toxicologists, clinical scientists, and students interested in the fields of pharmacology, biochemistry, and drug metabolism. |
| epclusa duration of therapy: Pocket Handbook of GI Pharmacotherapeutics George Y. Wu, Achilles Pappano, 2009-04-05 Although there are many pharmacology texts, and electronic sources of drug information relating to GI disorders, they are frequently encyclopedic, and practical information can be difficult to find. In Pocket Handbook of GI Pharmacotherapeutics, George Wu and Achilles Pappano create a text that combines the current treatment protocols and practical pharmacological information of prominent GI disorders for the first time. Chapters are disease specific, and contain treatment algorithms and therapy guides that present all the essential information in a compact, easy to reference handbook. The text contains practical clinical information in a highly accessible format, including keys for relative costs and the FDA pregnancy rating system for drug safety. Informative and unique, Pocket Handbook of GI Pharmacotherapeutics is a must have reference for any internist, gastroenterologist or general practioner who endeavors to provide better treatment of their patients. |
| epclusa duration of therapy: Blood Donor Counselling World Health Organization, 2016-06-24 Individuals who donate their blood provide a unique and precious gift in an act of human solidarity. In order to donate blood, prospective donors should be in good health and free from any infections that can be transmitted through transfusion. Most blood donors perceive themselves to be healthy, but some are unsuitable to donate blood due to the potential risk of compromising or worsening their own health or the risk of transmission of infections to patients. Blood transfusion services (BTS) have a duty of care towards blood donors as well as to the recipients of transfusion. This duty of care extends to prospective donors who are deferred from donation--whether on a temporary or permanent basis--as well as those who donate blood and are subsequently found to have unusual or abnormal test results. BTS have a responsibility to confirm test results and provide information, counseling and support to enable these individuals to understand and respond to unexpected information about their health or risk status. Counseling is part of the spectrum of care that a BTS should be able to provide to blood donors--including referral to medical practitioners or specialist clinical services. Pre-donation counseling was recognized as one element of the strategy to reduce and, if possible, prevent the donation of blood by individuals who might be at risk for HIV and other TTI including hepatitis B and C viruses as well as to inform the donor of the donation process and testing of blood for HIV. Post-donation counseling was acknowledged to be a necessary element of donor management as an adjunct to informing donors of unusual or abnormal test results. Blood donor counseling by trained specialist staff is now considered to be a key component of the blood system in most countries with a well-developed blood transfusion service. It may be required at a number of stages in the blood donation process or following blood screening and should be available at any point at which the BTS has an interface with donors. In many countries, however, blood donor counseling is not yet available in a structured way. Blood Donor Counselling: Implementation Guidelines has therefore been developed to provide guidance to blood transfusion services that have not yet established donor counseling programs. |
| epclusa duration of therapy: Viruses and Human Cancer Mei Hwei Chang, Kuan-Teh Jeang, 2013-09-06 Research on oncogenic viruses and related human cancers has advanced rapidly in the past decade. Most articles, however, focus on a specific oncogenic virus and cancer. There is consequently a need for a comprehensive, up-to-date monograph that offers broad and integrated knowledge. Viruses and Human Cancer – From Basic Science to Clinical Prevention is designed to meet this need by providing an advanced overview on the basic and clinical aspects of oncogenic viruses and the human cancers that they cause. Virology, virus-induced inflammation and tissue injuries, oncogenic mechanisms, epidemiology, and current and emerging preventive and therapeutic strategies are all discussed in detail. In addition, the book covers the individual aspects of seven oncogenic viruses, i.e., hepatitis B virus, hepatitis C virus, human papilloma virus, Epstein-Barr virus, human T-cell lymphotropic virus, Kaposi sarcoma-associated herpes virus, and Merkel cell polyomavirus, and the related human cancers. |
| epclusa duration of therapy: Managing Discovery in the Life Sciences Philip A. Rea, Mark V. Pauly, Lawton R. Burns, 2018-02-01 In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations. |
| epclusa duration of therapy: Coronaviruses and Other Novel Antiviral Targets Kathie Seley-Radtke, 2021-11-18 Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mechanism of action of the broadly acting antiviral drug remdesivir, Improving properties of the nucleobase analogue T-706 as a potential anti-SARS-CoV-2 and anti-influenza compound, Antivirals for RNA virus infections Anno 2020-2021, Broad spectrum antiviral fleximer nucleosides, SARS-CoV-2 main protease inhibitors, The search for antivirals to treat alphavirus infections, Inhibitors of Ebola Virus targeting Innate immune evasion, Uracil derivatives as non-nucleoside inhibitors of viral infections, and more. Provides the authority and expertise of leading contributors from an international board of authors Presents the latest release in the Annual Reports in Medicinal Chemistry Updated release includes the latest information on the Coronaviruses and other novel antiviral targets |
| epclusa duration of therapy: Current Trends and Concerns in Infectious Diseases I. W. Fong, 2021-03-07 A follow-up to Emerging Issues and Controversies in Infectious Diseases, this volume provides a comprehensive review of topical issues in infectious diseases, highlighting the controversies related to the newest findings and recommendations. Coverage includes trends and debates in HIV research, community-acquired pneumonia, H. pylori, progress in Hepatitis C treatment paired with the lack of progress on Hepatitis B, and the effects of climate change on infectious disease epidemiology, among others. This is an essential resource for practicing and academic physicians, investigators, residents, and fellows focused on infectious diseases, infection control, public health, and global health. |
| epclusa duration of therapy: Antibiotics Manual David L. Schlossberg, Rafik Samuel, 2017-08-10 A comprehensive compendium of all commonly used antibiotics, including indications, side effects, dosage information, and drug/food interactions Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition is a unique, user-friendly guide made for all who prescribe antibiotics. It’s the only book available that takes a 100% drug-listed approach to 200 of the most common antibiotics prescribed to patients each day. Presented in full color, it’s also a convenient reference for every clinician to consult once the decision to use a particular antibiotic has been reached. This edition of Antibiotics Manual includes newer antibiotics that have been released since the publication of the First Edition and updates prescribing information for the older antibiotics. This all-new Second Edition: Has a color-coded interior design which provides quick and easy point of care access for the user Includes 200 of the most commonly prescribed antibiotics, listed by both brand and generic names Features important recently-released antibiotics such as ceftaroline, tedizolid, and bedaquiline Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition is a welcome book for physicians in all specialties of medicine who prescribe antibiotics. It is also a handy tool for pharmacists, nurses, nurse practitioners, and physician assistants who want more information on the drugs they administer. |
| epclusa duration of therapy: Nursing2019 Drug Handbook Lippincott, 2013-02-12 THE #1 Drug Guide for nurses & other clinicians...always dependable, always up to date! Look for these outstanding features Completely updated nursing-focused drug monographs featuring over 3,650 generic, brand-name, and combination drugs in an easy A-to-Z format 37 brand-new FDA-approved drugs in this edition, including 33 complete monographs—tabbed and conveniently grouped in a handy “new drugs” section for easy retrieval More than 8,000 clinical updates—new dosages and indications, Black Box warnings, adverse reactions, nursing considerations, clinical alerts, and patient teaching information NEW logos highlighting biosimilar drugs and drugs with genetic-related considerations NEW appendix—Ophthalmic drugs: Indications and dosages Special focus on U.S. and Canadian drug safety issues and concerns Photoguide insert with images of 462 commonly prescribed tablets and capsules Plus FREE companion Toolkit available online through NDHnow.com Monthly FDA updates featuring newly approved drugs, indications, and warnings Pharmacology videos, audio pronunciation guide, and English-Spanish translator Equianalgesic dosing guidelines for opioid drugs Mechanisms and sites of action graphics for selected drugs NCLEX®-style questions, free CE tests, plus bonus discounts...and more! |
| epclusa duration of therapy: The APRN and PA’s Complete Guide to Prescribing Drug Therapy 2020 Mari J. Wirfs, PhD, MN, APRN, ANP-BC, FNP-BC, CNE, 2019-05-09 Includes more than 30 new diagnoses and eBook with digital updates as needed! Updated to deliver the most current standards, this is a unique prescribing reference for APRN students and advanced health care providers in all practice settings who need guidance on prescribing drugs for patients with acute, episodic, and chronic health problems. Concise, easy to read, and updated throughout, the resource delivers pharmacotherapy regimens for more than 600 diagnoses—including over 30 that are new. The print format includes an eBook with digital updates to assure immediate access to essential information. Listed alphabetically by diagnosis, pharmacotherapy regimens include, for each diagnosis, drug choices listed by generic name, FDA pregnancy category, generic/over-the-counter availability, adult/pediatric dosing regimens, brand names, forms of dosage, and additives. Clinically useful information such as laboratory values to be monitored, patient teaching points, and safety information is interspersed throughout each diagnosis. Additional quick-access features include information presented in convenient table format and an alphabetical cross-reference index of drugs by generic and brand name, with FDA pregnancy category and controlled drug schedule (I, II, III, IV, V). Key Features: Includes 31 new diagnoses totaling over 600 organized alphabetically Serves as a quick-access prescribing reference for APRN and PA students and health care providers in all primary care settings Presents drug information in condensed and summary form for ease of use Within each diagnosis, drug choices are listed alphabetically by generic /trade name, FDA pregnancy category, adult/pediatric dosing, dose forms, and additives Delivers guidance on lab values to be monitored, patient education points, and safety information Includes 30 Appendices with ready access to key drug classifications, FDA Pregnancy Categories, US Schedule of Controlled Substances, Immunization Schedules, Contraceptive Guidance, categories Anti-Infectives, and more! Offers brand/generic cross-reference |
| epclusa duration of therapy: Eliminating the Public Health Problem of Hepatitis B and C in the United States National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on a National Strategy for the Elimination of Hepatitis B and C, 2016-06-01 Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report. |
| epclusa duration of therapy: Manual for Pharmacy Technicians Bonnie S. Bachenheimer, 2019-08-15 The Trusted Training Resource for Pharmacy Technicians at All Levels The role of pharmacy technicians is rapidly expanding, and demand for well-trained technicians has never been higher! Technicians are assuming more responsibilities and are taking on greater leadership roles. Quality training material is increasingly important for new technicians entering the field, and current technicians looking to advance. Look no further than the new 5th edition of the best-selling Manual for Pharmacy Technicians to master the practical skills and gain the foundational knowledge all technicians need to be successful. |
| epclusa duration of therapy: Decision Making in HCV Ashm, 2016-06-30 |
| epclusa duration of therapy: The APRN and PA's Complete Guide to Prescribing Drug Therapy 2024 Mari J. Wirfs, PhD, MN, APRN, ANP-BC, FNP-BC, CNE, 2024-02-15 An unrivaled reference tool for advanced practice providers and students in clinical practice settings This concise and easy-to-read drug therapy prescribing reference provides critical information for advanced practice nurses and physician assistants in clinical practice settings who are involved in the primary care management of patients with acute, episodic, and chronic health problems, life-altering and life-threatening diseases, and needs for health promotion and disease prevention. Interspersed with clinically useful information, such as monitored laboratory values, patient teaching points, and safety information, this reference draws upon data taken directly from FDA-approved drug labels and patient medication guides, and is organized by diagnosis rather than by drug classification, to provide advanced practice practitioners with the comprehensive, concise, and up-to-date information on drug therapies that they need to help achieve positive outcomes in their daily practice. The first section of this book presents drug treatment regimens for over 700 clinical diagnoses, listed alphabetically by generic name, followed by important information required for prescription decision-making. The second section provides additional information on treatment, organized in a convenient table format. An alphabetical cross-reference index of drugs allows for easy identification of alternate drug names and their location within the text. New to this Edition: Information on over 100 new diagnoses and over 100 new generic drugs indicated for the treatment of quality of life-altering and life-threatening conditions such as chronic kidney disease, genetic diseases, mesothelioma, MS, metastatic cancers, and rare diseases. Updates on drugs used for site-specific cancers, mental health issues, and commonly diagnosed diseases such as diabetes and asthma. Details on new drug approvals including indications, treatment regimens, adverse reactions, drug-drug interactions, warnings and precautions, and use in special populations Key Features: Provides new drug treatment regimens for drugs that are first in class, novel drugs, orphan drugs, new drugs with breakthrough or fast track designation and drugs with new indications and expanded social populations. Includes drug prescribing information on diseases prevalent outside of North America, including endemic diseases with known transmission and treatment interventions. Serves advanced practice providers across the United States and internationally. Consistent with approvals and recommendations for use by the FDA. |
| epclusa duration of therapy: Conn's Current Therapy 2023 - E-Book Rick D. Kellerman, David P. Rakel, 2022-11-02 Trusted by clinicians for more than 75 years, Conn's Current Therapy presents today's evidence-based information along with the personal experience and discernment of expert physicians. The 2023 edition is an excellent resource for a wide range of healthcare professionals, including primary care, subspecialists, and allied health, providing current treatment information in a concise yet in-depth format. Nearly 350 topics have been carefully reviewed and updated to bring you state-of-the-art content in even the most rapidly changing areas of medicine. - Offers personal approaches from recognized leaders in the field, covering common complaints, acute diseases, and chronic illnesses along with the most current evidence-based clinical management options. - Follows a consistent, easy-to-use format throughout, with diagnosis, therapy, drug protocols, and treatment pearls presented in quick-reference boxes and tables for point-of-care answers to common clinical questions. - Includes new chapters on leg edema and venous stasis, multisystem inflammatory syndrome in children (MIS-C), monoclonal antibodies, and genetic testing. - Incorporates more electronic links throughout the text that connect the reader to apps and clinical prediction tools that can easily be accessed in practice. - Features thoroughly reviewed and updated information from many new authors and two new associate editors, Drs. Joel J. Heidelbaugh and Ernestine M. Lee, who offer a fresh perspective and their unique personal experience and judgment. - Provides current drug information thoroughly reviewed by PharmDs. - Features nearly 300 images, including algorithms, anatomical illustrations, and photographs, that provide useful information for diagnosis. |
| epclusa duration of therapy: Therapeutic Update Jill E. Maddison, 1996 |
| epclusa duration of therapy: Liver Diseases Florentina Radu-Ionita, Nikolaos T. Pyrsopoulos, Mariana Jinga, Ion C. Tintoiu, Zhonghua Sun, Ecaterina Bontas, 2020-01-10 This book provides an in-depth coverage not only of liver pathology but also of diagnosis of the numerous types of liver disease, placing specific emphasis on current treatments of liver pathology including the most up-to-date information on liver transplantation. The first part of provides an in-depth account of the liver pathology in different conditions such as Hepatits, liver ischaemia reperfusion injury, Lyme disease, cirrhotic cardiomyopathy and hepatocellular carcinoma. The second part provides a comprehensive overview of diagnostic methods. Of particular interest are chapters on the latest techniques in Patient-specific 3D printing and transient elastography (FibroScan). The final part focuses on treatment and provides a step-by step guide to the therapeutic management of liver diseases starting with pharmacological treatment and techniques including surgery and liver transplantation. This is an invaluable book for clinicians, practitioners including academics, scientists/researchers and postgraduates to provide the newest knowledge in the field of liver pathogenesis. It is written by a multidisciplinary team of experts in hepathology, gastroenterology, and surgery especially from liver transplantation. |
| epclusa duration of therapy: Viral Polymerases Satya Prakash Gupta, 2018-10-29 Viral Polymerases: Structures, Functions and Roles as Antiviral Drug Targets presents in-depth study information on the structure and functions of polymerases and their roles in the lifecycle of viruses, and as drug targets. Viral polymerases constitute a vital component in the lifecycle of many viruses, such as human immunodeficiency virus (HIV), hepatitis viruses, influenza virus, and several others. They are essentially required for the replication of viruses. Thus, the polymerases that can be found in viruses (called viral polymerases) represent favorable targets for the design and development of antiviral drugs. - Provides comprehensive, state-of-the-art coverage on virus infections, the virus lifecycle, and mechanisms of polymerase inhibition - Analyzes the structure-activity relationships of inhibitors of each viral polymerase - Presents a consistent and comprehensive coverage of all aspects of viral polymerases, including structure, function and their role as antiviral drug targets |
| epclusa duration of therapy: Conn's Current Therapy 2021, E-Book Rick D. Kellerman, David P. Rakel, 2020-12-08 Designed to suit a wide range of healthcare providers, including primary care, subspecialties, and allied health, Conn’s Current Therapy has been a trusted clinical resource for well over 70 years. The 2021 edition continues this tradition of excellence with current, evidence-based treatment information presented in a concise yet in-depth format. More than 300 topics have been carefully reviewed and updated to bring you state-of-the-art information in even the most rapidly changing areas of medicine. Offers personal approaches from recognized leaders in the field, covering common complaints, acute diseases, and chronic illnesses along with the most current evidence-based clinical management options. Follows a consistent, easy-to-use format throughout, with diagnosis, therapy, drug protocols, and treatment pearls presented in quick-reference boxes and tables for point-of-care answers to common clinical questions. Includes new and significantly revised chapters on COVID-19, Diabetes Mellitus in Adults, Chronic Leukemias, and Osteomyelitis. Incorporates more electronic links throughout the text that connect the reader to apps and clinical prediction tools that can easily be accessed in practice. Features thoroughly reviewed and updated information from many new authors who offer a fresh perspective and their unique personal experience and judgment. Provides current drug information thoroughly reviewed by PharmDs. Features nearly 300 images, including algorithms, anatomical illustrations, and photographs, that provide useful information for diagnosis. |
| epclusa duration of therapy: Conn's Current Therapy 2020, E-Book Rick D. Kellerman, KUSM-W Medical Practice Association, 2019-12-07 Designed to suit a wide range of healthcare providers, including primary care, subspecialties, and allied health, Conn’s Current Therapy has been a trusted clinical resource for more than 70 years. The 2020 edition continues this tradition of excellence with current, evidence-based treatment information presented in a concise yet in-depth format. More than 300 topics have been carefully reviewed and updated to bring you state-of-the-art information even in the most rapidly changing areas of medicine. Offers personal approaches from recognized leaders in the field, covering common complaints, acute diseases, and chronic illnesses along with the most current evidence-based clinical management options. Follows a consistent, easy-to-use format throughout, with diagnosis, therapy, drug protocols, and treatment pearls presented in quick-reference boxes and tables for point-of-care answers to common clinical questions. Includes new and significantly revised chapters on neurofibromatosis, autism, psoriatic arthritis, and postpartum depression. Features thorough updates in areas critical to primary care, including Acute Myocardial Infarction • Hypertension • Peripheral Arterial Disease • Valvular Heart Disease • Hepatitis C • Irritable Bowel Syndrome • Obsessive Compulsive Disorder • Chronic Obstructive Pulmonary Disease • Fibromyalgia • Menopause • Travel Medicine • and more. Provides current drug information thoroughly reviewed by PharmDs. Shares the knowledge and expertise of new contributors who provide a fresh perspective in their specialties. Features nearly 300 images, including algorithms, anatomical illustrations, and photographs, that provide useful information for diagnosis. |
| epclusa duration of therapy: Comprehensive Medicinal Chemistry III Samuel Chackalamannil, David Rotella, Simon Edward Ward, Jörg Holenz, Ana Martinez, Carmen Gil, Helmut Buschmann, Norbert Handler, Andrea Wolkerstorfer, Andrew M. Davis, Colin Edge, Alan G. E. Wilson, Ian Collins, William Watkins, Louis J. Lombardo, Ved Srivastava, Adrian Hall, Santhosh Neelamkavil, Rob Jones, 2017 |
| epclusa duration of therapy: New Drug Development for Known and Emerging Viruses Helga Rübsamen-Schaeff, Helmut Buschmann, 2022-01-31 Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic. New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. Covers the entire field of antiviral drug discovery and development Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2 Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies. |
| epclusa duration of therapy: HCV: The Journey from Discovery to a Cure Michael J. Sofia, 2020-02-07 Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume HCV: The Journey from Discovery to a Cure - Volume I. |
| epclusa duration of therapy: Genotyping Ibrokhim Y. Abdurakhmonov, 2018 A rare norovirus (NoV) genotype GII.17 has recently emerged and rapidly became predominant in most East Asian countries in the winters of 2014-2015. In this study, we report the diversity of NoV GII.17 in detail; a total of 646 GII.17 sequences obtained during 1978-2015 were analyzed and subjected to meta-analysis. At least five major recombinant GII.17 clusters were identified. Each recombinant variant group appeared to have emerged following the time order: GII.P4-GII.17 (1978-1990), GII.P16-GII.17 (2001-2004), GII.P13-GII.17 (2004-2010), GII.Pe-GII.17 (2012-2015) and GII.P3-GII.17 (2011-2015). The newly emerged GII.P3-GII.17 variant, which exhibited significant sequence and structure variations, is evolving toward a unique lineage. Our results indicate that circulation of GII.17 appears to change every 3-5 years due to replacement by a newly emerged variant and that the evolution of GII.17 is sequentially promoted by inter-genotype recombination, which contributes to the exchange between non-GII.17 and GII.17 RdRp genes and drives the evolution of GII.17 capsid genes. |
| epclusa duration of therapy: Pharmaceutical Prices in the 21st Century Zaheer-Ud-Din Babar, 2014-12-05 This book provides an overview of the global pharmaceutical pricing policies. Medicines use is increasing globally with the increase in resistant microbes, emergence of new treatments, and because of awareness among consumers. This has resulted in increased drug expenditures globally. As the pharmaceutical market is expanding, a variety of pharmaceutical pricing strategies and policies have been employed by drug companies, state organizations and pharmaceutical pricing authorities. |
| epclusa duration of therapy: Tarascon Pocket Pharmacopoeia 2019 Deluxe Lab-Coat Edition J. in Chief J. Hamilton MD FAAEM FACMT FACEP, 2018-12-07 Used by physicians, pharmacists, nurses, physician assistants, dentists and medical transcriptionist, the Tarascon Pocket Pharmacopoeia® 2019 Deluxe Lab-Coat Edition continues its tradition as the leading portable drug reference packed with vital drug information to help clinicians at point of care. |
| epclusa duration of therapy: Companion and Complementary Diagnostics Jan Trøst Jørgensen, 2019-05-08 Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation provides readers with in-depth insights into the individual steps in the development of companion diagnostic assays, from the early biomarker discovery phase straight through to final regulatory approval. Further, the clinical implementation of companion diagnostic testing in the clinic is also discussed. As the development of predictive or selective biomarker assays linked to specific drugs is substantially increasing, this book offers comprehensive information on this quickly-evolving area of biomedicine. It is an essential resource for those in academic institutions, hospitals and pharma, and biotech and diagnostic commercial companies. - Covers all aspects, from biomarker discovery, to development and regulatory approval - Explains the how to aspects of companion diagnostics - Incorporates information on the entire process, allowing for easier and deeper understanding of the topic |
Epclusa for Hep C: Uses, Dosage, Side Effects & Warnings
Apr 12, 2024 · Epclusa is an antiviral treatment for chronic hepatitis C in adults and children 3 years of age and older. Epclusa is a once-a-day medicine containing two antiviral medicines, …
Epclusa Información Española De la Droga - Drugs.com
Epclusa sofosbuvir 400 mg / velpatasvir 100 mg (GSI 7916) View larger images Drugs.com Mobile App Access drug & treatment information, identify pills, check interactions and set up personal …
Epclusa: Package Insert / Prescribing Info - Drugs.com
EPCLUSA is available as tablets or pellets for oral use. Each dosage form is available in two dose strengths: 400 mg/100 mg Tablets: pink, diamond-shaped, film-coated tablet debossed with …
Epclusa Patient Tips: 7 things you should know - Drugs.com
Aug 28, 2023 · Epclusa is a combination tablet containing velpatasvir and sofosbuvir. It may be used to treat all six genotypes of the hepatitis C virus in adults and children over the age of …
Epclusa Interactions Checker - Drugs.com
Epclusa sofosbuvir 400 mg / velpatasvir 100 mg (GSI 7916) View larger images Drugs.com Mobile App Access drug & treatment information, identify pills, check interactions and set up personal …
Epclusa Side Effects: Common, Severe, Long Term - Drugs.com
Aug 19, 2024 · Note: This document provides detailed information about Epclusa Side Effects associated with sofosbuvir / velpatasvir. Some dosage forms listed on this page may not apply …
Can you drink alcohol while taking Epclusa? - Drugs.com
Jun 4, 2024 · Drinking alcohol while taking Epclusa may increase the risk of cirrhosis and liver failure. Although drinking alcohol is not strictly contraindicated with Epclusa treatment, it …
How long is an Epclusa treatment? - Drugs.com
May 27, 2025 · Epclusa can also cause serious side effects like a slow heart rate or reactivation of the hepatitis B virus. Before starting treatment with Epclusa, your healthcare provider will do …
Epclusa Dosage Guide - Drugs.com
Jun 5, 2024 · The recommended dosage of EPCLUSA in pediatric patients 3 years of age and older is based on weight and provided in Table 2. Table 3 provides the weight-based dosage …
Does Epclusa cure Hep C, what is the success rate? - Drugs.com
Jun 4, 2024 · Epclusa has a 98% overall cure rate in all 6 of the main types of hepatitis C in patients without cirrhosis (a serious liver disease) or with compensated cirrhosis (mild or no …
Epclusa for Hep C: Uses, Dosage, Side Effects & Warnings
Apr 12, 2024 · Epclusa is an antiviral treatment for chronic hepatitis C in adults and children 3 years of age and older. Epclusa is a once-a-day medicine containing two antiviral medicines, …
Epclusa Información Española De la Droga - Drugs.com
Epclusa sofosbuvir 400 mg / velpatasvir 100 mg (GSI 7916) View larger images Drugs.com Mobile App Access drug & treatment information, identify pills, check interactions and set up …
Epclusa: Package Insert / Prescribing Info - Drugs.com
EPCLUSA is available as tablets or pellets for oral use. Each dosage form is available in two dose strengths: 400 mg/100 mg Tablets: pink, diamond-shaped, film-coated tablet debossed with …
Epclusa Patient Tips: 7 things you should know - Drugs.com
Aug 28, 2023 · Epclusa is a combination tablet containing velpatasvir and sofosbuvir. It may be used to treat all six genotypes of the hepatitis C virus in adults and children over the age of …
Epclusa Interactions Checker - Drugs.com
Epclusa sofosbuvir 400 mg / velpatasvir 100 mg (GSI 7916) View larger images Drugs.com Mobile App Access drug & treatment information, identify pills, check interactions and set up …
Epclusa Side Effects: Common, Severe, Long Term - Drugs.com
Aug 19, 2024 · Note: This document provides detailed information about Epclusa Side Effects associated with sofosbuvir / velpatasvir. Some dosage forms listed on this page may not apply …
Can you drink alcohol while taking Epclusa? - Drugs.com
Jun 4, 2024 · Drinking alcohol while taking Epclusa may increase the risk of cirrhosis and liver failure. Although drinking alcohol is not strictly contraindicated with Epclusa treatment, it …
How long is an Epclusa treatment? - Drugs.com
May 27, 2025 · Epclusa can also cause serious side effects like a slow heart rate or reactivation of the hepatitis B virus. Before starting treatment with Epclusa, your healthcare provider will do …
Epclusa Dosage Guide - Drugs.com
Jun 5, 2024 · The recommended dosage of EPCLUSA in pediatric patients 3 years of age and older is based on weight and provided in Table 2. Table 3 provides the weight-based dosage …
Does Epclusa cure Hep C, what is the success rate? - Drugs.com
Jun 4, 2024 · Epclusa has a 98% overall cure rate in all 6 of the main types of hepatitis C in patients without cirrhosis (a serious liver disease) or with compensated cirrhosis (mild or no …
